AI assistant
Sending…
Terns Pharmaceuticals, Inc. — Director's Dealing 2025
Feb 26, 2025
32559_dirs_2025-02-25_91d06503-e510-47a5-87c3-4a03df7e5521.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2025-02-24
Reporting Person: Gengos Andrew (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-24 | Stock Option (Right to Buy) | $3.73 | A | 750000.00 | Acquired | 2035-02-23 | Common Stock (750000.00) | Direct |
Footnotes
F1: 25% of the shares subject to the option vest on the first anniversary measured from February 24, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.